Back to results
US 2025/0082664 A1Published application
Nucleoside formulation
AssigneePhion Therapeutics Ltd.
InventorsHelen MCCARTHY, Lindsey Ann BENNIE, Philip CHAMBERS
Life of this patent
Estimating the term…
Abstract
The present specification relates to a nucleoside formulation which comprises a nucleoside or a phosphate thereof; and an amphipathic cell penetrating RALA peptide. In one embodiment, the nucleoside formulation comprises gemcitabine or a phosphate thereof and the peptide WEARLARALARALARHLARALARALRACEA.
Claims19
A nucleoside formulation comprising:
- (i) gemcitabine or a phosphate thereof;
- and
- (ii) an amphipathic cell penetrating peptide comprising or consisting of the amino acid sequence:
- (SEQ ID_No 1)
- WEARLARALARALARHLARALARALRACEA
- or a sequence with at least 80% sequence identity or homology.
3 more elements
A nucleoside formulation comprising:
- (i) 0.2-0.5% w/w gemcitabine triphosphate;
- (ii) 3.5-4.5% w/w an amphipathic cell penetrating peptide consisting of the amino acid sequence WEARLARALARALARHLARALARALRACEA (SEQ ID_No 1);
- (iii) 95-97% w/w trehalose;
- formulated as an isotonic formulation in water with an osmolality of 290-310 mOsmol/kg.
1 more element
Dependencies are inferred from the claim text.